INDV.L

Indivior Plc
Indivior PLC - Chair Succession Plan
3rd October 2024, 13:30
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8750G
Indivior PLC
03 October 2024
 

INDIVIOR PLC

CHAIR SUCCESSION PLAN

 

Richmond, VA, and Slough, UK, October 3, 2024 - Indivior PLC (Nasdaq/LSE: INDV) today announces that Graham Hetherington has informed the Board of his intention to retire as Chair and from the Board at the end of 2024 for personal reasons. Graham has been a member of the Board for five years, including four years as Chair of the Board.

The Nomination Committee, led by the Senior Independent Director, Juliet Thompson, has commenced a comprehensive search process to identify Graham's successor.

The Board would like to express its sincere thanks to Graham for his significant contribution to Indivior since joining the Board in 2019.

Graham Hetherington commented:

"It has been a privilege to serve as Chair of Indivior, working closely with an outstanding Board and highly dedicated management team who have an unwavering commitment to develop life-transforming treatments for patients suffering from substance use disorders, serious mental illness and overdose."

Key Contacts:

Jason Thompson

VP, Investor Relations

+1 804-402-7123 or jason.thompson@indivior.com

 

Tim Owens

Director, Investor Relations

+1 804-263-3978 or timothy.owens@indivior.com

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.

 

Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD.  Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFSFFDDELSESS]]>
TwitterFacebookLinkedIn